LB PHARMACEUTICALS INC
LBRXNASDAQTrading Snapshot
- Day Range
- $39.23 – $40.76
- 52-Week Range
- $14.32 – $50.16
- Volume (shares)
- 400,678
- Avg Volume (shares)
- —
- Shares Outstanding
- 32.3M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -13.4
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-2.84
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +12.7%
LB PHARMACEUTICALS INC
LBRX
StockOtter · stockotter.spaceAbout LB PHARMACEUTICALS INC
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
LB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in Schizophrenia
LB Pharmaceuticals NASDAQ: LBRX outlined its clinical and commercial plans for LB-102, an investigational antipsychotic designed as a structural modification of amisulpride, during its first R&D Day in New York. The comp
LB Pharmaceuticals to Participate in Upcoming Investor Events
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that a
LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that a
LB Pharmaceuticals Inc (NASDAQ:LBRX) Stock Has Average Target Price of $49.62
LB Pharmaceuticals Inc (NASDAQ: LBRX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has
LB Pharmaceuticals: One Methyl Group, Two Enantiomers, And A Bullish $5 Billion Opportunity
LB Pharmaceuticals earns a buy rating, with a base case valuation of $85 per share and potential upside to $150 if Phase 3 and clinical differentiation succeed. LB-102's N-methyl modification enables effective brain rece
LB Pharmaceuticals Appoints Susan G. Kozauer, M.D.
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that